Morris Animal Foundation accepting canine cancer research proposals

Article

Encourages individuals from historically marginalized groups to apply to diversify animal health research community

MikeFusaro / stock.adobe.com

MikeFusaro / stock.adobe.com

Morris Animal Foundation is now accepting proposals for canine cancer research with a particular interest in studies in the areas of genetic epidemiology, genetic and epigenetic changes predictive of cancer risk, development of diagnostic and therapeutic biomarkers, and tumor genomic profiling.1

According to an organizational release,1 the foundation is looking for projects that maximize specimens and information from the Golden Retriever Lifetime Study,2 but also welcomes submissions using other data.

“The Golden Retriever Lifetime Study provides a unique opportunity to understand the origins of canine cancer,” said Kathy Tietje, PhD, MBA,chief program officer at Morris Animal Foundation, in the release. “We encourage the scientific community to include Study resources in their research proposals.”

Additionally, Morris Animal Foundation encourages fellowship applications from those from historically marginalized groups. These Minority Fellowships are being funded by Sally R. McIntosh through the Donor-Inspired Study program. McIntosh aims to offer fellowship funding to support applicants from historically marginalized groups interested in studying canine health to make "a tiny dent" in diversifying the animal health research community.1

Interested researchers can find more information on Morris Animal Foundation’s Grants page. Proposals are due August 16, 2023.

References

  1. Canine cancer focus of latest Morris Animal Foundation call for research proposals. News release. Morris Animal Foundation. June 7, 2023. Accessed June 7, 2023.
  2. Golden retriever lifetime study. Morris Animal Foundation. Accessed June 7, 2023. https://www.morrisanimalfoundation.org/golden-retriever-lifetime-study
Recent Videos
Image Credit: © Przemyslaw Iciak - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.